✦ LIBER ✦

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer

✍ Scribed by Jamie L. Lesnock; Coreen Farris; Thomas C. Krivak; Kenneth J. Smith; Maurie Markman

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Consolidation paclitaxel is more cost-ef

✍ J. Lesnock; C. Farris; T. Krivak; K. Smith; M. Markman 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 303 KB

Is paclitaxel a more cost-effective choi

✍ Kushnir, C.L.; Frick, K.; Zhao, Z.; Giuntoli, R.L. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 101 KB

Is maintenance paclitaxel a more cost-ef

✍ Kushnir, C.; Zhao, N.; Frick, K.; Giuntoli, R. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 46 KB